Lurasidone filed with EMA for schizophrenia
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP) has said that the European Medicines Agency (EMA) has accepted for review Takeda's marketing authorisation application (MAA) for the oral atypical antipsychotic, lurasidone hydrochloride, for the treatment of schizophrenia.The once-daily medication was discovered and developed by DSP and licensed to Takeda in March 2011, granting the latter exclusive commercialisation rights for lurasidone in 26 EU member states (excluding the UK), and Switzerland, Norway, Turkey and Russia. (The companies undertook joint responsibility for the drug's development.)
You may also be interested in...
Topotarget reconfirms mid-2013 US NDA for belinostat as it looks to Q3 milestone
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca wins EU approval of rare thyroid cancer drug vandetanib
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Solid but not spectacular: Victoza's weight loss verdict in non-diabetics
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.